News Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Apr 30, 2025, 16:05 ET REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Apr 15, 2025, 08:01 ET Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
for the launch of YESAFILI™ no later than July 1, 2025. YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual
More news about: Biocon Biologics Ltd.